H.R. 3701: Family Vaccine Protection Act
The bill, titled the Family Vaccine Protection Act, aims to amend the Public Health Service Act by officially codifying the Advisory Committee on Immunization Practices (ACIP). This committee plays a crucial role in guiding vaccine use and recommendations in the United States. Here are the main elements of the bill:
Codification of the Advisory Committee
The bill establishes the ACIP in law and defines its responsibilities, ensuring it operates under the guidelines specified in the Federal Advisory Committee Act. The ACIP will continue to provide advice and recommendations on the use of vaccines and related agents based on the best scientific evidence available.
Responsibilities of the Advisory Committee
- The ACIP will issue recommendations regarding vaccines for the control of vaccine-preventable diseases in the civilian population.
- Any recommendations made must be based on extensive, peer-reviewed scientific evidence, and the Director of the Centers for Disease Control and Prevention (CDC) is required to adopt these recommendations unless they contradict the evidence.
- If the Director does not adopt a recommendation, they must provide a public justification and inform Congress within 48 hours.
Vaccine Consideration Procedures
In cases where new vaccines are licensed, or new indications for existing vaccines are introduced, the ACIP will consider these vaccines promptly and notify Congress about their recommendations.
The committee will prioritize recommendations on vaccines designated as breakthrough therapies during public health emergencies.
Emergency Use and Revision of Recommendations
The ACIP is also responsible for providing guidance on vaccines authorized for use in emergency situations. It can revise or withdraw recommendations based on new scientific evidence regarding vaccine safety and efficacy.
Administrative Support and Reporting
The bill stipulates that the ACIP will receive administrative support from the CDC, ensuring effective management and operation. The committee will also submit reports to the Director of the CDC and inform other relevant health officials about its recommendations.
Meetings and Membership
The ACIP is required to hold at least three public meetings annually and can establish subcommittees to focus on specific issues. Membership will include a chairperson and 15-19 members with expertise in various fields related to immunization and public health.
Funding
The legislation authorizes $2.8 million in funding annually for the operational costs of the ACIP from fiscal years 2026 to 2029, which includes compensation and travel expenses for its members and staff support.
Implications for Vaccine Injury Compensation
The bill also amends the National Vaccine Injury Compensation Program, indicating that any modifications to the Vaccine Injury Table must be supported by substantial evidence regarding vaccine safety and efficacy.
Relevant Companies
- PFE (Pfizer Inc.): As a major vaccine manufacturer, Pfizer could be impacted by regulatory changes regarding vaccine recommendations.
- MRNA (Moderna, Inc.): Similar to Pfizer, any changes in recommendations for vaccines they produce could affect their market dynamics.
- JNJ (Johnson & Johnson): Changes in the advisory committee's recommendations could influence their vaccine offerings and market presence.
This is an AI-generated summary of the bill text. There may be mistakes.
Sponsors
34 bill sponsors
-
Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
-
Co-Sponsor
Actions
2 actions
Date | Action |
---|---|
Jun. 04, 2025 | Introduced in House |
Jun. 04, 2025 | Referred to the House Committee on Energy and Commerce. |
Corporate Lobbying
0 companies lobbying
None found.
* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.